Abstract:Exosomes are extracellular vesicles with a diameter in the range of 50-200 nm and a double-layer lipid membrane structure that are released by various types of cells under normal or abnormal physiological conditions. At present, according to their extensive biological functions, exosomes have been used in a wide range of research fields and applications, including as potential biomarkers and drug delivery vehicles. Intrahepatic cholangiocarcinoma is a malignant tumor of the biliary epithelium with the characteristics of cholangiocellular differentiation, which accounts for 10%-15% of all types of primary liver cancer. Intrahepatic cholangiocarcinoma has no obvious clinical symptoms in the early stages, which results in a low survival rate. Imaging equipment dependent diagnostic methods and currently commonly used diagnostic markers with low sensitivity/specificity have necessitated the development of new specific markers for intrahepatic cholangiocarcinoma. In this study, exosomes were isolated from serum using a commercial kit and characterized through nanoparticle tracking analysis, Western blotting analysis, and transmission electron microscopic analysis to prove the successful isolation of exosomes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that the protein profiles of the serum and serum exosome samples were significantly different. In particular, some high-abundance proteins in the serum samples were significantly reduced or disappeared in the serum exosome sample. Meanwhile, some protein bands (which may belong to exosomes) that did not appear in the serum samples appeared in the serum exosome samples, leading to the conduciveness of subsequent mass spectrometry analysis. The serum and serum exosome samples of the healthy control and intrahepatic cholangiocarcinoma groups were analyzed by liquid chromatography-mass spectrometry for label-free quantitative proteomics. In total, 547 proteins were identified in the serum exosome samples, of which 341 (more than 60%) could be found in the exosomal protein database. In addition, 271 and 430 credible proteins were screened from the serum and serum exosome samples for multi-dimensional statistical analysis and differential protein discovery. Unsupervised principal component analysis and supervised orthogonal partial least squares discriminant analysis based on the quantitative proteome of the serum and serum exosome samples could distinguish the healthy control and intrahepatic cholangiocarcinoma groups well, which illustrates that the two types of samples both have potential in the diagnosis of intrahepatic cholangiocarcinoma. There were 15 upregulated and 8 downregulated proteins screened in the intrahepatic cholangiocarcinoma group compared to the healthy control group based on the serum samples, while 33 upregulated and 18 downregulated proteins were screened in the intrahepatic cholangiocarcinoma group compared to the healthy control group based on the serum exosome samples, and only four of the differential proteins screened based on the two types of samples were duplicates. At the same time, 35 of the 51 differentially expressed proteins screened based on serum exosome samples belonged to the exosomal protein database. Finally, biological information analysis was performed according to these differential proteins. The molecular functions, biological processes, and signal pathways enriched by these differential proteins mainly involved the innate immune responses, inflammatory responses, and blood coagulation. This study provides a reference value for potential biomarker discovery and exploration of the process of occurrence, development, and metastasis of intrahepatic cholangiocarcinoma. Moreover, compared with proteomic analysis based on serum samples, proteomic analysis based on serum exosome samples can be used to identify more differential proteins and biological information, and although these differential proteins and biological information may show big differences, the specificity and sensitivity of exosome-based diagnosis and the superiority of exosomes as samples for proteomic analysis has proven the application value of exosomes.

Research Status of Biliary Proteomics in Primary Liver Cancer Patients

A Comparative Proteomic Analysis of Bile for Biomarkers of Cholangiocarcinoma

Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers

An optimized and improved method for bile proteomic analysis

Proteomics in Primary Biliary Cholangitis.

Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer.

Proteomic-Based Analysis for Identification of Potential Serum Biomarkers in Gallbladder Cancer

Research Progress of Lipolipomics in Primary Hepatocellular Carcinoma

Comparative Proteomic Profiling Of Human Bile Reveals Ssp411 As A Novel Biomarker Of Cholangiocarcinoma

[Proteomic analysis of serum and serum exosomes, and their application in intrahepatic cholangiocarcinoma]

Study on Proteomics in Hepatic Metastasis of Colorectal neoplasms

Detection of Differential Expression of Serum Protein in Peripheral Blood by SELDI-TOF-MS Technology in Cholangiocarcinoma

EXPRESSION OF P-GLYCOPROTEIN(PGP) AND HEPATITIS B VIRUS X PROTEIN IN THE PRIMARY TUMOR OF LIVER CNACER AND PORTAL VEIN CANCER EMBOLUS AND ITS CLINICAL SIGNIFICANCE

Research progress of proteomics and prediction of metastasis and recurrence in hepatocellular carcinoma

Comparative Proteomic Analysis of Serum from Cholangiocarcinoma Patients and Normal Cohorts

Application of Proteomics in Hepatocellular Carcinoma

The application of proteomics in different aspects of hepatocellular carcinoma research.

Proteomic Identification of Tumor Biomarkers Associated with Primary Gallbladder Cancer

Study on serum proteomics in primary biliary cirrhosis by using functionalized magnetic beads and MALDI-TOF-MS technique: a preliminary study

Bile Metabolic Fingerprints Distinguish Biliary Tract Cancer from Benign Biliary Diseases

The characterization of serum proteomics and metabolomics across the cancer trajectory in chronic hepatitis B‐related liver diseases